A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects With Chronic Hepatitis B and Who Are Currently Not on Treatment

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects With Chronic Hepatitis B and Who Are Currently Not on Treatment

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Aug 2017

At a glance

  • Drugs Vesatolimod (Primary) ; Tenofovir disoproxil fumarate
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 14 Aug 2017 Planned End Date changed from 18 Oct 2019 to 1 Oct 2019.
    • 26 Jan 2017 Planned End Date changed from 1 Oct 2019 to 18 Oct 2019.
    • 01 Aug 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top